Earnings Releases·Oct 28, 2026, 4:03 PM ET

MiMedx Group, Inc. — Third Quarter 2026 Earnings Summary

Net sales declined 45% year-over-year to $62 million driven by a 71% drop in Wound sales, though Surgical product sales rose 9%; the company reported a net loss of $9 million versus $17 million in net income the prior year.
The company achieved positive Adjusted EBITDA of $2.1 million (3.3% margin) and eliminated all debt by repaying its $17 million term loan, while cash reserves decreased to $121 million.
Full-year 2026 net sales guidance remains unchanged at $250–$260 million, with management projecting sequential Q4 Adjusted EBITDA growth and long-term targets of low double-digit sales growth and >20% EBITDA margins.
Strategic progress includes the Surgical franchise now comprising nearly two-thirds of sales, a favorable court ruling vacating the FDA's biological product classification for AXIOFILL®, and a $25 million patent licensing settlement with a competitor.
The company continues to pursue the Sanara MedTech acquisition subject to FTC review, while noting that future sales face risks from Medicare reimbursement changes and market competition.